• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Neuro-Oncology Practice

    Neuro-Oncology Practice

    JournalISSN 2054-2577eISSN 2054-2585中科院 医学 4区

    年发文量

    研究主题

    论文(953)

    排序
    1[18F]DOPA PET Identifies Metabolically Active Tumor Beyond Contrast-Enhancing Margins in IDH-WT Glioblastoma: A Histopathology and Fluorescence Validation Study
    Andrea Bianconi,Alessandro Pesaresi,Raffaele de Marco,Michela Zotta,Luca Bertero,Francesco Bruno,Edoardo Pronello,Giulia Capella,Flavio Panico,Adriana Lesca,Fabio Cofano,Paola Cassoni,

    Abstract Background Supramaximal resection in IDH-wildtype glioblastoma (GB) improves survival, yet identifying tumor infiltration within FLAIR-hyperintense peritumoral areas remains challenging. This study aims to validate the use of [18F]DOPA PET for identifying metabolically active tumor beyond contrast-enhancing (CE) margins, correlating imaging with histopathology and intraoperative fluorescence. Methods Patients with newly diagnosed IDH-WT GB scheduled for supramaximal resection and undergoing preoperative DOPA-PET and MRI were prospectively enrolled from the ResPGlioma study. The Biological Tumor Volume (BTV) was semi-automatically delineated using the contralateral striatal SUVmean as the PET positivity threshold. Before resection, biopsy samples were collected from five radiologically distinct areas: CE, FLAIR+PET (FP), PET-only (Po), FLAIR-only (Fo), and normal tissue (N). Each sample was blindly assessed for neoplastic, necrotic, and infiltrative components, mitotic count, microvascular proliferation. Intraoperative 5-aminolevulinic acid (5-ALA) and fluorescein sodium (FS) uptake were also recorded. Results Twenty-five samples from 5 patients were analyzed. The BTV, defined using a striatal SUVmean threshold, extended beyond CE-MRI margins in 100% of cases (mean BTV 30.4 ± 17.6 cm³ vs. mean CE volume 20.6 ± 16.9 cm³). PET-positive areas (FLAIR+/PET+ and PET-only) showed significantly higher neoplastic cell density and mitotic counts compared to FLAIR-only (P < .005) and normal areas (P < .005). No significant histopathological differences were found between PET-only and CE regions, whereas FLAIR-only samples primarily exhibited white matter infiltration and reactive changes. Uptake of 5-ALA and SF was significantly more intense and frequent in PET-positive areas (CE, FP, Po) compared to Fo and N areas (P = .015 and P < .001, respectively). Conclusions This preliminary study provides histopathological and fluorescence validation that [18F]DOPA PET identifies areas of high tumor burden within the peritumoral zone, comparable to the contrast-enhancing core. The integration of amino acid PET in preoperative planning should be considered to guide targeted supramaximal resection of metabolic hotspots in IDH-wildtype glioblastoma.

    2026
    引用
    AI阅读
    加入学术空间
    2Real-world Outcomes of Biosimilar Bevacizumab-Bvzr Versus Reference Agent in the Management of Patients with IDH Wild-Type Glioblastoma
    Sanghee Lim, Sara L. Maloney,U. Sener, S. Caron, S. Kizilbash, J. Campian,Bryan J. Neth, I. Carabenciov, J. Uhm, M. Ruff

    Bevacizumab, an anti-VEGF monoclonal antibody, has become a mainstay in the management of malignant gliomas. Multiple bevacizumab biosimilars have been approved since initial FDA approval of the reference agent and have seen widespread use, in part due to reduced costs. However, real-world data evaluating comparability between reference and biosimilar agents, especially for the management of glioblastoma, remain limited. We performed a retrospective analysis of patients treated with reference bevacizumab (Avastin ®) versus those receiving bevacizumab-bvzr (Zirabev ®), a widely used biosimilar agent for the management of IDH wild-type glioblastoma at our institution between 2019 and 2022. Outcomes of interest included rates of dose-limiting adverse effects associated with anti-angiogenic therapy, as well as survival as measured by overall survival (OS). A total of 129 patients were included in our final analysis; 71 received reference drug (bevacizumab) while 58 received the biosimilar agent (bevacizumab-bvzr). Rates of dose-limiting adverse effects were similar between both groups (OR 1.2013, p = 0.7418). On analysis of the entire cohort, concomitant treatment with anticoagulation (OR 3.3045, p = 0.0238) was associated with a higher risk of dose-limiting adverse effects On survival analysis, we found that OS was similar between the bevacizumab (median OS 714 daysdays) and biosimilar (median OS 631 days) groups by both univariate (p = 0.5639). and multivariate (HR 1.0869, p = 0.6916) analyses. Bevacizumab-bvzr demonstrated similar clinical efficacy and safety profile compared to reference bevacizumab in our institutional cohort of IDH-WT glioblastoma patients.

    2026
    引用
    AI阅读
    加入学术空间
    3Acute Spine Tumor Pain: Development of a Description and Classification System Through an International Delphi Consensus Study
    O. Barzilai, M. Vial,R. Charest-Morin, Han-Bo Chen,Dean Chou, M. Clarke,Nicolas Dea, J. O'Toole, L. Doan, S. Karim, D. Lubelski, S. Lo,

    Pain is a dominant and often debilitating symptom in patients with spinal tumors, yet its assessment and reporting remain inconsistent across disciplines. The absence of a standardized, mechanism-based classification limits clinical communication, treatment selection, and the interpretation of outcomes in spine oncology research We conducted a modified Delphi study through the AO Spine Knowledge Forum Tumor, engaging an international panel of 44 multidisciplinary experts, including neurosurgeons, orthopedic surgeons, radiation oncologists, and pain specialists. Across four iterative rounds, participants evaluated candidate domains and definitions for spine tumor pain using structured surveys, consensus thresholds, and a final consensus meeting. A mechanism-based classification framework was developed based on agreement across predefined criteria. Consensus identified three core domains—pain characteristics, clinical examination, and imaging findings—as essential for characterizing spine tumor–related pain. These elements informed a simplified, mechanism-based classification comprising six mutually exclusive categories: mechanical-axial, mechanical-radicular, inflammatory-axial, inflammatory-radicular, neuropathic-central, and neuropathic-peripheral. The framework integrates symptom quality, anatomical distribution, and radiographic correlates to infer underlying pain mechanisms. Nociplastic and chronic pain states were incorporated as modifiers. The resulting system was considered clinically intuitive, reproducible, and applicable across specialties. This international consensus establishes the first multidisciplinary, mechanism-based classification of acute spine tumor pain. The framework provides a standardized approach to pain assessment in neuro-oncology, with potential to improve clinical decision-making, enhance cross-disciplinary communication, and enable consistent pain endpoint reporting in clinical trials. Prospective validation is warranted to confirm its reliability and utility in diverse clinical settings.

    2026
    引用
    AI阅读
    加入学术空间
    4Neighborhood Socioeconomic Disadvantage is Associated with Overall Survival in IDH-Mutant Glioma
    Krithi Gopinath,William Adams, Carolina Pusec,Amy J Kind,Pallavi Tiwari,Alvaro A Sandino, Alexander Remsik,Michael C Veronesi,Vivek Prabhakaran,Veena Nair, Taylor McMillan,Brett Morris,

    Abstract Background Neighborhood socioeconomic disadvantage influences outcomes across many cancer types, yet its role in IDH-mutant gliomas remains unexplored. Because these tumors have a prolonged disease course, they may have unique vulnerabilities to socioeconomic disparity. We examined the association between the Area Deprivation Index (ADI) and clinical outcomes in patients with IDH-mutant gliomas. Methods We conducted a retrospective cohort study of 193 adults with histologically and molecularly confirmed IDH-mutant gliomas per the WHO 2021 criteria, who were all treated at a single academic center from 1994-2025. State ADI deciles were derived from patients’ ZIP codes at diagnoses. Primary outcomes were overall survival (OS) and time to next intervention (TTNI) or death. We used univariable and multivariable survival models, adjusting for age at diagnosis, extent of resection, and histology. Results The median follow up was 7.7 years and median OS was 18.7 years. Patients from high-ADI neighborhoods (state decile greater than or equal to four) had significantly higher mortality than patients from low-ADI neighborhoods (HR = 3.02, 95% CI: 1.43--6.36; p = .004). ADI was not significantly associated with TTNI in primary analysis (HR = 1.52, p = .06), though a repeated measures sensitivity analysis demonstrated a significant association (HR = 1.70, p = .01). Oligodendroglioma histology and greater extent of resection were protective for both outcomes. Conclusions Neighborhood socioeconomic disadvantage is associated with worse overall survival in IDH-mutant glioma after adjusting for age, extent of resection, and histology. Ensuring equitable access to longitudinal care across socioeconomic strata may mitigate survival disparities in this population.

    2026
    引用
    AI阅读
    加入学术空间
    5Intraoperative Neurophysiological Monitoring and Survival Outcomes in Patients with IDH–wildtype Glioblastoma
    Giorgio Fiore,Giulio Andrea Bertani,Giorgio Giovanni Carrabba,Mauro Pluderi,Stefano Borsa,Giorgio Conte,Maurizio Vergari,Stefania Navone,Laura Guarnaccia,Filippo Cogiamanian,Giovanni Marfia,Manuela Caroli,

    Abstract Background Intraoperative neurophysiological monitoring (IONM) facilitates safe glioma resection in eloquent regions. Its effect on survival in molecularly defined IDH–wildtype glioblastoma remains uncertain. We assessed the association between IONM-supported surgery and survival outcomes in this high-risk population and explored subgroups deriving the greatest benefit. Methods We retrospectively analyzed 200 adults who underwent first-time resection for IDH–wildtype glioblastoma between 2012 and 2021. Co-primary outcomes were progression-free survival (PFS) and overall survival (OS), evaluated through Kaplan–Meier estimates and multivariable Cox models. Secondary 1:1 propensity score-matched analyses were performed based on age, preoperative KPS, MGMT methylation status, preoperative tumor volumes and localization. Volumetric analysis included contrast-enhancing (CE) and non–CE tumor components. Subgroup analyses were stratified by tumor location. Results In the unmatched cohort, IONM was independently associated with prolonged PFS (HR 0.60, 95% CI 0.45–0.84) and OS (HR 0.60, 95% CI 0.43–0.83), along with younger age, MGMT methylation, higher KPS, and smaller postoperative volumes. IONM patients had higher complete CE resection rates (64.2% vs 40.4%, P = 0.0005) and improved functional preservation (postoperative KPS 80 vs. 70, P = 0.008), despite more early deficits. In the location-matched cohort (n = 104), median PFS was 12 months with IONM vs 7 months without (P = 0.0007), and OS was 17 vs 11 months (P = 0.0018). Supramaximal resections occurred exclusively in the IONM group. The benefit was most evident in frontal, parietal, and insular tumors. Conclusions IONM-supported surgery was associated with more extensive resection, functional preservation, and longer survival in IDH–wildtype glioblastoma. IONM was more frequently used in tumors located in frontal, parietal, and insular regions, consistent with the functional complexity of these areas.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 953 篇论文

    高被引作者

    作者引用发文
    Jill S. Barnholtz-Sloan46216
    Martin Taphoorn43024
    Quinn Ostrom41213
    Roy E Strowd4046
    Linda Dirven39125
    Maciej M. Mrugala3827
    Michael Weller36822
    Terri S. Armstrong36230
    Justin Jordan3523
    Andrea Wasilewski3462

    高产作者

    作者引用发文
    Terri S. Armstrong36230
    Linda Dirven39125
    Martin Taphoorn43024
    Michael Weller36822
    Mark R. Gilbert18719
    Susan M. Chang17819
    Boele Florien W17419
    Karin Piil7419
    Jeffrey S. Wefel8618
    Johan A F Koekkoek22617

    相关期刊

    Neurosurgery clinics of North America
    Journal of Neuro-Oncology
    Brain Tumor Pathology
    Neuro-oncology
    Journal of oncology practice
    CNS oncology
    Brain tumor research and treatment
    Oncology and therapy
    Glioma (Mumbai, India)
    Neuro-oncology advances